Ulcerative Colitis Market Research, 2030
The global ulcerative colitis market was valued at $6.2 billion in 2020, and is projected to reach $10.8 billion by 2030, growing at a CAGR of 5.7% from 2021 to 2030. Ulcerative colitis is a most common form of inflammatory bowel disease which affects several people. It causes inflammation and ulcers in digestive tract. Ulcerative colitis affects the innermost lining of large intestine and rectum. Ulcerative colitis develops at any age, but is commonly developed in people between the age of 15 and 30. The symptoms of ulcerative colitis vary from person to person and may include diarrhea, passing blood with your stool, and abdominal immune response.
Growth of the global ulcerative colitis market is majorly driven by increase in prevalence of inflammatory gastrointestinal disorders, increase in the cases of ulcerative colitis, and development of drugs for treatment of ulcerative colitis by large number of key players. According to a survey conducted by Marc D Basson on Ulcerative Colitis in 2019, in the U.S., one million people were affected with ulcerative colitis. Prevalence of ulcerative colitis is the main reason for development of drugs to treat ulcerative colitis. Thus, with rise in burden of inflammatory bowel disease demand for ulcerative colitis increases, which, in turn, is anticipated to foster the growth of the ulcerative colitis market. Furthermore, according to a research study by Wing Yan Mak et al. published in Journal of Gastroenterology and Hepatology, in 2020, in Europe, North America, and Australia 23-34% of ulcerative colitis patients presented were with proctitis. In addition, in May 2021, Bristol Myers Squibb received approval from the U.S. Food and Drug Administration for the use of Zeposia for treating adults with moderately to severely active ulcerative colitis, a chronic inflammatory bowel disease. Therefore, rise in development of new drugs led to increase in the growth of the ulcerative colitis market opportunity.
Market Segmentation
The ulcerative colitis market is segmented on the basis of route of administration, disease type, and molecule type. Depending on route of administration, it is categorized into oral and injectables. According to disease type, it is classified into mild ulcerative colitis, moderate ulcerative colitis, and severe ulcerative colitis. By molecule type, it is divided into small molecules and biologics.
Region-wise, the market is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (Japan, China, Australia, India, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, Saudi Arabia, South Africa, and rest of LAMEA).
Segment Overview
Injectables segment would witness the fastest growth, registering a CAGR of 6.4% during the forecast period.
By Route Of Administration
Depending on route of administration, the oral segment dominated the ulcerative colitis market forecast, and this trend is expected to continue during the forecast period, owing to increase in R&D activities in the pharmaceutical & medical device industry, rise in demand for drugs required for treatment, and surge in adoption of various types of ulcerative colitis drugs. However, the injectables segment is expected to witness considerable growth during the forecast period, owing to increase in number of ulcerative colitis cases and growth in number of key players for development of new drugs in the medical device industry.
By Disease Type
Moderate UC segment is projected to be the dominating segment throughout the forecast period.
By Disease Type
By disease type, the mild UC segment was the major contributor in 2020, and is expected to maintain its lead of ulcerative colitis market share during the forecast period, owing to increase in number of inflammatory bowel diseases, rise in the number of ulcerative colitis, and increase in demand for the treatment of ulcerative colitis. However, the moderate UC is expected to witness considerable ulcerative colitis market growth during the forecast period due to increase in number of ulcerative proctitis and rise in development of new ulcerative colitis drugs in the clinical laboratories. These are the factors which is bossting the ulcerative colitis market size.
By Molecule Type
Small Molecules segment would exhibit a CAGR of 6.2% during forecast period.
By Molecule Type
On the basis of molecule type, the small molecule segment dominated the ulcerative colitis industry in 2020, and this trend is expected to continue during the forecast period, owing to large number key players offering drugs for treatment of ulcerative colitis and advancement in R&D activities. However, the biologics segment is expected to witness considerable growth during the forecast period, owing to increase in inflammatory gastrointestinal diseases and surge in usage of ulcerative colitis drugs.
By Region
Asia-Pacific is expected to experience growth at the highest rate, registering a CAGR of 6.5% during the forecast period.
By Region Type
Region wise, North America dominated the market in 2020, and is expected to be dominant during the forecast period, owing to rise in number of ulcerative colitis disease, presence of key players, development of the healthcare sector, and presence of new drugs in the region. However, Asia-Pacific is expected to register the highest CAGR of 6.5% from 2021 to 2030, owing to increase in prevalence of inflammatory bowel disease and development of healthcare infrastructure.
The key players that operate in the global ulcerative colitis market include Abbott Laboratories, Ajinomoto, Astrazeneca Plc., Eli-Lilly, GlaxoSmithKline Plc., Index Pharmaceuticals Holdings AB, Johnson & Johnson, Merck & Co., Pfizer Inc., and Sanofi.
Key Benefits for Stakeholders
- This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the ulcerative colitis market analysis from 2020 to 2030 to identify the prevailing ulcerative colitis market opportunities.
- The market research is offered along with information related to key drivers, restraints, and opportunities.
- Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
- In-depth analysis of the ulcerative colitis market segmentation assists to determine the prevailing market opportunities.
- Major countries in each region are mapped according to their revenue contribution to the global market.
- Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
- The report includes the analysis of the regional as well as global ulcerative colitis market trends, key players, market segments, application areas, and market growth strategies.
Ulcerative Colitis Market Report Highlights
| Aspects | Details |
 Market Size By 2030 | USD 10.8 billion |
 Growth Rate | CAGR of 5.7% |
 Forecast period | 2020 - 2030 |
 Report Pages | 225 |
 By Disease Type |
|
 By Molecule Type |
|
 By Route of Administration |
|
 By Region |
|
 Key Market Players | Merck & Co. Inc., INDEX PHARMACEUTICALS HOLDINGS AB, Abbott Laboratories, AstraZeneca plc, AJINOMOTO CO. INC., Pfizer Inc., GLAXOSIMITHKLINE PLC, SANOFI S.A, JOHNSON & JOHNSON, ELI-LILLY |
Analyst Review
This section provides opinions of top level CXOs in the ulcerative colitis market. According to the insights of CXOs, increase in number of inflammatory bowel disease, rise in geriatric population, and advancements in new drug launches are all attributed to propel growth of the ulcerative colitis market.
CXOs further added increase in consumer awareness & demand for preventive healthcare services, rise in demand for healthcare services from overall population, and new advancements in disease treatment are predicted to broaden ulcerative colitis clinical applications. In addition, increase in number of products approval contributes toward growth of the market.
The market gains interest of healthcare companies, owing to focus on preventive facilities provided to patients who undergo critical inflammatory bowel disease treatment which are more complex than other health conditions. This leads to increase in utilization of ulcerative colitis drugs ,which provides lucrative opportunity for the growth of the market.
North America is expected to witness highest growth, in terms of revenue, owing to rise in geriatric population, presence of key players, and advancements in healthcare investments. Asia-Pacific was the second largest contributor to the market in 2020, and is expected to register fastest CAGR during the forecast period, owing to increase in number of inflammatory gastrointestinal disease and unmet needs for innovative ulcerative colitis drugs. However, stringent government regulations toward approval of biosimilars restrain the market growth during the forecast period.
The upcoming trends of Ulcerative Colitis Market are large number key players offering drugs for treatment of ulcerative colitis and advancement in R&D activities, also increase in number of inflammatory bowel diseases, rise in the number of ulcerative colitis, and increase in demand for the treatment of ulcerative colitis.
The leading application of Ulcerative Colitis Market are mild ulcerative colitis, moderate ulcerative colitis, and severe ulcerative colitis.
North America is the largest regional market for Ulcerative Colitis.
Ulcerative Colitis is estimated to reach $1,764.66 million by 2030, growing at a CAGR of 5.7% from 2021 to 2030.
The top companies to hold the market share in Ulcerative Colitis are Abbott Laboratories, Ajinomoto, Astrazeneca Plc., Eli-Lilly, GlaxoSmithKline Plc., Index Pharmaceuticals Holdings AB, Johnson & Johnson, Merck & Co., Pfizer Inc., and Sanofi.
Loading Table Of Content...
Loading Research Methodology...
